wherein L, R1 and R2 are as defined herein, as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders, such as e.g. mood disorders, anxiety, schizophrenia, Alzheimer's disease, Parkinson's disease and multiple sclerosis."/>
公开/公告号EP3263566A1
专利类型
公开/公告日2018-01-03
原文格式PDF
申请/专利权人 H. LUNDBECK A/S;
申请/专利号EP20170178046
申请日2011-12-22
分类号C07D401/12;
国家 EP
入库时间 2022-08-21 13:14:58